Co-Diagnostic' Technology to Deliver Accessible, High-Fidelity Gold Standard PCR Testing Like No Other

Send us Fan MailIn this episode of WTR Small-Cap Spotlight, host Tim Gerdeman and analyst Robert Sassoon speak with Dwight Egan, CEO of Co-Diagnostics Inc. (NASDAQ: CODX), about the company’s evolution from a pandemic-era PCR testing provider to a diversified molecular diagnostics leader. In our discussion, Egan highlights the Co-DX PCR Pro, a portable, cost-effective device that delivers gold-standard PCR testing outside the lab and explains how its patented Co-Primer multiplexing technology sets it apart from competitors. Our conversation also covers Co-Diagnostics’ “razor-and-blade” business model, its pipeline of testing capabilities targeting high-impact infectious diseases, the role of AI in manufacturing and diagnostic optimization, and the commercial strategies needed to achieve long-term financial success.